Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. ownership update: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared voting and dispositive power over 958,768 shares of Common Stock, representing 5.7% of the class as of the close of business on May 14, 2026. The cover page footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 0 shares. The filing attributes voting and investment power to Point72 Associates under an investment management agreement; Point72 Capital Advisors Inc. is the general partner and Mr. Cohen controls both entities.
Sirenia Capital Management and Alex Silverstein report beneficial ownership of Common Stock in Q32 Bio Inc. The filing states a reported position of 2,057,308 shares, representing 9.9% of the class on a fully‑exercised basis subject to a 9.99% blocker. The percentage calculation uses 14,629,463 shares outstanding as of March 1, 2026. The filing also discloses 1,025,654 shares issuable upon exercise of reported warrants held by the Sirenia Fund and notes the blocker limits exercise to prevent ownership above 9.99%.
Q32 Bio Inc. received an updated Schedule 13D/A from OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC reporting their current stake in the company. Through OrbiMed Private Investments VII, LP, they beneficially own 2,252,987 shares of common stock, representing about 13.3% of Q32 Bio’s 16,956,415 shares outstanding as referenced in a recent quarterly report. The filing notes this percentage fell by more than 1% because the total shares outstanding increased, not because OrbiMed sold shares. OrbiMed states it may buy more or sell shares over time depending on Q32 Bio’s performance and market conditions. An OrbiMed employee, Diyong Xu, sits on Q32 Bio’s board, and any equity awards he receives as a director are assigned back to OrbiMed’s fund. The filing also highlights a registration rights agreement requiring Q32 Bio to file a shelf registration to allow resale of certain shares issued in connection with a prior financing and merger.
Opaleye Management Inc., Opaleye, L.P. and James Silverman filed an amended Schedule 13G reporting shared beneficial ownership of 1,256,228 shares of Q32 Bio Inc. Common Stock, representing 8.59% of the class. The filing states the interest is based on 14,629,463 shares outstanding as of March 1, 2026, as reported in Q32 Bio's Form 10-K. The statement explains the Fund directly holds the shares, the Adviser serves as investment adviser, and Mr. Silverman controls the Adviser; the joint filing agreement is included.
Q32 Bio Inc. is a clinical-stage biotech focused on bempikibart for alopecia areata and other autoimmune diseases. For the quarter ended March 31, 2026, it reported a net loss of $7.6 million, improved from $11.0 million a year earlier, as research and development expenses fell to $3.2 million and general and administrative costs to $4.5 million.
Cash and cash equivalents were $50.8 million, with total cash, cash equivalents, restricted cash and restricted cash equivalents of $51.4 million. Management believes this is sufficient to fund operations for at least one year from the financial statement issuance date, though the company expects continued operating losses and will likely need additional capital over time.
During the quarter, Q32 completed a registered direct offering, issuing 1,666,679 shares of common stock and pre-funded warrants for net proceeds of $10.4 million. It also put in place an at-the-market equity program allowing sales of up to $14.2 million of common stock under an effective shelf registration, with no ATM shares sold by March 31, 2026. After quarter-end, the company sold 2,326,952 shares under the ATM for $13.8 million in net proceeds and expanded the ATM capacity by filing a prospectus supplement for up to an additional $75 million.
Q32 Bio Inc. reported a smaller net loss for the quarter ended March 31, 2026 while advancing its lead alopecia areata program. Net loss was $7.6 million, or $0.54 per share, compared with $11.0 million, or $0.90 per share, a year earlier, driven by lower research and development and general and administrative expenses.
Cash and cash equivalents were $50.8 million as of March 31, 2026. Together with a completed $10.5 million registered direct offering, $14.2 million from the ATM program and guaranteed near-term milestone payments, the company expects its financial runway to extend into the first half of 2028. Q32 Bio expects 36-week topline data from the Part B Phase 2a SIGNAL-AA trial of bempikibart in mid-2026 and has begun dosing patients in an open-label extension.
Q32 Bio Inc. is asking stockholders to vote at its all-virtual 2026 annual meeting on June 12, 2026. Investors will elect three Class II directors to terms running to the 2029 meeting, ratify Ernst & Young LLP as auditor for 2026, and cast a non-binding advisory vote on executive pay. The record date is April 15, 2026, when 15,629,463 common shares were outstanding. The board unanimously recommends voting FOR all three proposals and offers multiple ways to vote by internet, phone, mail, QR code, or during the virtual meeting.
Q32 Bio Inc. entered a new phase of its at-the-market stock offering program by filing an additional prospectus supplement that covers up to $75,000,000 of common stock to be sold through Cantor Fitzgerald & Co. under an existing Controlled Equity Sales Agreement.
The company previously sold $14,200,000 of common stock under an earlier prospectus supplement, which is now fully used and terminated. Future sales of the additional shares, if any, will be made under Q32 Bio’s effective Form S-3 shelf registration statement.
Q32 Bio Inc. is registering $75,000,000 of common stock for sale from time to time through or to Cantor Fitzgerald & Co. under a Controlled Equity Sales Agreement as an at-the-market offering. The sales agent may act as agent or principal and is entitled to a 3.0% commission on gross proceeds. The company previously sold $14,200,000 under the prior prospectus supplement and has terminated that prior supplement. The number of shares outstanding was 12,858,047 as of December 31, 2025, and the prospectus assumes an illustrative price of $6.48 per share.
Net proceeds will be received by the issuer and are planned for working capital and clinical development, including support of bempikibart (ADX-914) development in alopecia areata. Sales may occur at varying prices and times; Cantor has no obligation to sell any set amount and the offering may be suspended or terminated per the sales agreement.